BackFirst Tracks Biotherapeutics Overview
First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics Target Price

Analysts' average 12-month price target for First Tracks Biotherapeutics is $64.

Get informed when a big investor buys or sells

+ Follow

Share Price

$45.05

Average Target Price

$64.4043% upside

15 analysts in the last 4 months

High: $100 | Low: $44

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-13Evercore ISI$7055.4% upsideOpen
2026-10-13Canaccord Genuity$6033.2% upsideOpen
2026-10-12Wells FargoDerek Archila$7055.4% upsideOpen
2026-10-09Wells Fargo$6237.6% upsideOpen
2026-09-30Canaccord Genuity$5011% upsideOpen
2026-09-18Evercore ISI$6544.3% upsideOpen
2026-09-16Guggenheim$100122% upsideOpen
2026-08-13Piper Sandler$95110.9% upsideOpen
2026-08-13H.C. Wainwright$5726.5% upsideOpen
2026-08-13Barclays$6544.3% upsideOpen
2026-08-10UBS$6544.3% upsideOpen
2026-07-28Wedbush$6033.2% upsideOpen
2026-07-28Wells FargoDerek Archila$5522.1% upsideOpen
2026-07-21Barclays$486.5% upsideOpen
2026-07-10H.C. WainwrightEmily Bodnar$442.3% downsideOpen
2026-06-08Wells FargoDerek Archila$3033.4% downsideOpen
2026-05-04Piper SandlerYasmeen Rahimi$5419.9% upsideOpen
2026-04-28H.C. WainwrightEmily Bodnar$3033.4% downsideOpen
2026-04-24Leerink PartnersDavid Risinger$462.1% upsideOpen
2026-04-21UBSMichael Yee$450.1% downsideOpen

First Tracks Biotherapeutics (TRAX) FAQ

As of the most recent data, TRAX shows a target price of $64. Scroll down for historical charts and peer comparison views.

If First Tracks Biotherapeutics moved to the average analyst target of $64, shares would be roughly 43.0% higher than $45.05. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of First Tracks Biotherapeutics's earnings trajectory.

Besides this target price page, Stockcircle has First Tracks Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $64) with ownership activity and broader fundamentals.

First Tracks Biotherapeutics's target price is $64; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.